Interferon-alpha 2 was initially approved for use in hairy cell leukemia (HCL) after studies showed that IFN-a2 demonstrated a high response rate in patients with progressive HCL (Golomb et al., 1986; Kirkwood et al., 2012). Here, IFNA2 is linked to hairy cell leukemia.